Free Trial

Penumbra (PEN) Stock Price, News & Analysis

Penumbra logo
$269.62 -3.02 (-1.11%)
Closing price 03:59 PM Eastern
Extended Trading
$269.50 -0.13 (-0.05%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Penumbra Stock (NYSE:PEN)

Key Stats

Today's Range
$268.66
$274.58
50-Day Range
$227.26
$272.96
52-Week Range
$184.80
$310.00
Volume
304,909 shs
Average Volume
494,656 shs
Market Capitalization
$10.52 billion
P/E Ratio
71.71
Dividend Yield
N/A
Price Target
$300.44
Consensus Rating
Moderate Buy

Company Overview

Penumbra Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

PEN MarketRank™: 

Penumbra scored higher than 95% of companies evaluated by MarketBeat, and ranked 34th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Penumbra has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Penumbra's stock forecast and price target.
  • Earnings Growth

    Earnings for Penumbra are expected to grow by 36.51% in the coming year, from $3.67 to $5.01 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Penumbra is 71.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.24.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Penumbra is 71.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.63.

  • Price to Earnings Growth Ratio

    Penumbra has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Penumbra has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Penumbra's valuation and earnings.
  • Percentage of Shares Shorted

    4.18% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Penumbra does not currently pay a dividend.

  • Dividend Growth

    Penumbra does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.18% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Penumbra has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Penumbra this week, compared to 14 articles on an average week.
  • Search Interest

    Only 6 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,649,681.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Penumbra is held by insiders.

  • Percentage Held by Institutions

    88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Penumbra's insider trading history.
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PEN Stock News Headlines

Leaked Gov’t Memo Reveals $100 Trillion Deadline
Only Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.tc pixel
Penumbra Appoints Shruthi Narayan as New President
See More Headlines

PEN Stock Analysis - Frequently Asked Questions

Penumbra's stock was trading at $237.48 at the beginning of the year. Since then, PEN shares have increased by 13.6% and is now trading at $269.8070.

Penumbra, Inc. (NYSE:PEN) released its quarterly earnings results on Tuesday, July, 29th. The company reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.05. The firm's quarterly revenue was up 13.4% on a year-over-year basis.
Read the conference call transcript
.

Penumbra's Board of Directors authorized a share repurchase program on Tuesday, August 13th 2024, which authorizes the company to buy back $200,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Penumbra's top institutional investors include Vanguard Group Inc. (9.90%), State Street Corp (3.00%), Champlain Investment Partners LLC (1.91%) and Geode Capital Management LLC (1.81%). Insiders that own company stock include Adam Elsesser, Johanna Roberts, Lambert Shiu, Maggie Yuen, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing, Arani Bose and Thomas Wilder.
View institutional ownership trends
.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
7/29/2025
Today
9/02/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:PEN
CIK
1321732
Employees
4,500
Year Founded
2004

Price Target and Rating

High Price Target
$350.00
Low Price Target
$263.00
Potential Upside/Downside
+11.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.76
Trailing P/E Ratio
71.75
Forward P/E Ratio
73.51
P/E Growth
2.45
Net Income
$14.01 million
Net Margins
11.54%
Pretax Margin
13.54%
Return on Equity
11.55%
Return on Assets
8.76%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
6.75
Quick Ratio
4.04

Sales & Book Value

Annual Sales
$1.19 billion
Price / Sales
8.81
Cash Flow
$2.86 per share
Price / Cash Flow
94.45
Book Value
$29.99 per share
Price / Book
9.00

Miscellaneous

Outstanding Shares
39,000,000
Free Float
37,049,000
Market Cap
$10.52 billion
Optionable
Optionable
Beta
0.45

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:PEN) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners